Clinical Trials

Multiple clinical trials are currently evaluating interventions across therapeutic areas such as substance use disorders, renal transplantation, Dercum's disease, and atrial septal defects. Spanning Phase 2 protocols as well as non-applicable or unspecified phases, these studies are supported by academic centers like Virginia Polytechnic Institute and State University and Assistance Publique - Hôpitaux de Paris, alongside industrial entities including Caliway Biopharmaceuticals Co. Ltd. and Lifetech Scientific (Shenzhen) Co. Ltd. All of these trials currently maintain a recruitment status of not yet recruiting.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05103514 Not yet recruiting
Substance Use Disorders
Virginia Polytechnic Institute and State University
2025-07-01 --
NCT06406179 Not yet recruiting
Renal Transplantation
Assistance Publique - Hôpitaux de Paris
2024-06-01 Not Applicable
NCT06303570 Not yet recruiting
Dercum''s Disease
Caliway Biopharmaceuticals Co. Ltd.
2024-06-28 Phase 2
NCT05887700 Not yet recruiting
Atrial Septal Defect
Lifetech Scientific (Shenzhen) Co. Ltd.
2024-05 --

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Glycolaldehyde dimer product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Glycolaldehyde dimer functions as an active endogenous metabolite that reacts with biological amine targets such as amino acids, generating reactive adducts that alter protein structural integrity and disrupt downstream metabolic biochemical pathways. These cellular alterations modulate biochemical homeostasis and physiological responses, providing mechanistic relevance to clinical investigations spanning substance use disorders, renal transplantation, Dercum's disease, and atrial septal defects.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.